FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Friday

 

Study Finds Aubagio Well-tolerated and Efficient in Long-term MS Treatment


























Researchers at the University of Texas Health Science Center at Houston, in collaboration with various institutions from north America and Europe, found that teriflunomide (Aubagio) is well-tolerated and efficient for long-term treatment of multiple sclerosis (MS).

The findings, entitled “Long-term safety and efficacy of teriflunomide,” were published in Neurology, the official journal of the American Academy of Neurology.

From the therapeutic standpoint, no cure has yet to be developed for MS, but many medications are currently available to relieve the symptoms and slow down disease progression. Among them, teriflunomide, also known by its brand name Aubagio (Genzyme) is approved for relapsing-remitting multiple sclerosis (RRMS) with 2-year positive results.

“Three randomized placebo-controlled trials in relapsing MS supported the registration and approval of teriflunomide for RRMS treatment. Collectively, these studies demonstrated the efficacy of teriflunomide on disability, annualized relapse rate (ARR), and MRI [magnetic resonance imaging] markers of disease. The trials demonstrated a consistent safety and tolerability profile for teriflunomide used for 2 years,” the authors wrote in their article.

In the extension study (NCT00803049) of the phase 3 Teriflunomide Multiple Sclerosis Oral (TEMSO) trial (NCT00134563), the researchers investigated the long-term (9-year) safety and efficacy of teriflunomide treatment.

A total of 742 MS patients were included in the extension study, in which patients treated with teriflunomide continued on the basis of the original dosage, and those receiving placebo prior to the extension were randomized 1:1 to teriflunomide 14 mg or 7 mg.

The results showed that teriflunomide is well-tolerated for long-term exposure exceeding 190 weeks per patient, and among 468 patients (63%) remained on treatment. With respect to adverse events (AEs), no significant change was recorded from those obtained at the core study, based mainly on increased transient liver enzymes or reversible hair thinning attributable to the switch from placebo to teriflunomide. Around 11% of patients discontinued the treatment due to AEs, and 20% experienced serious AEs.

Relapse rates and gadolinium-enhancing T1 lesion counts reduced in patients when the extension study began due to the switch from placebo to teriflunomide, and was maintained low afterward. Also, disability was maintained stable in all treated groups.

“Overall, the results of this study provide further evidence that the effects of teriflunomide are maintained with longer term treatment and also support previous observations that teriflunomide has a well-characterized and manageable long-term safety profile,” concluded the researchers.

Story Source: The above story is based on materials provided by MULTIPLESCLEROSISNEWSTODAY
Note: Materials may be edited for content and length

Labels: ,



Go to Newer News Go to Older News